Disc Medicine upgraded at Raymond James as bitopertin ‘uber bull case plays out’
The Fly

Disc Medicine upgraded at Raymond James as bitopertin ‘uber bull case plays out’

As previously reported, Raymond James analyst Danielle Brill upgraded Disc Medicine (IRON) to Strong Buy from Outperform with a price target of $110, up from $66, after the company announced that its its end-of-Phase 2 meeting with the FDA for bitopertin in erythropoietic porphyrias, or EPP resulted in agreement on all proposed attributes of the APOLLO study. The “uber bull case scenario played out” as the FDA is amenable to an accelerated approval filing using PPIX reduction as a surrogate biomarker of efficacy, which allows Disc to file using the data generated-to-date, the analyst tells investors.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App